Health Research


Lymphoma: A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies

Basic Study Information

Will the new study drug, eFT508, be useful as a cancer treatment in the future?
This research study has two parts. Part 1 will test the safety and tolerability of the study drug at different doses and using different ways of taking the drug (powder mixed with a liquid diluent [suspension] taken once per day or capsules taken once or twice per day) to determine the recommended dose. Part 2 will test what effects the study drug has on the cancer and the safety of the study drug when given at the recommended dose.
Cancer Center
clinicaltrials.gov/ct2/show/NCT02937675?term=eFT508-0002&rank=1
ILYM17002

Lead Researcher (Principal Investigator)

Paul Barr

Study Contact Information

Yelena Lerman
(585) 276-8333

Additional Study Information

More Information

About this Study

TrialLink

Learn More About These Conditions